Zentalis Pharmaceuticals, Inc.
ZNTL
$1.79
-$0.025-1.38%
| Weiss Ratings | ZNTL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | ZNTL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | ZNTL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.57 | |||
| Price History | ZNTL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -7.51% | |||
| 30-Day Total Return | 7.53% | |||
| 60-Day Total Return | -42.23% | |||
| 90-Day Total Return | -34.62% | |||
| Year to Date Total Return | -40.50% | |||
| 1-Year Total Return | -87.35% | |||
| 2-Year Total Return | -89.77% | |||
| 3-Year Total Return | -95.71% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -88.87% | |||
| 52-Week Low % Change | 12.42% | |||
| Price | ZNTL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $16.27 | |||
| 52-Week Low Price | $1.61 | |||
| 52-Week Low Price (Date) | Feb 04, 2025 | |||
| 52-Week High Price (Date) | Apr 01, 2024 | |||
| Valuation | ZNTL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 128.99M | |||
| Enterprise Value | -219.00M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.53 | |||
| Earnings Per Share Growth | -45.69% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.17 | |||
| Price/Book (Q) | 0.36 | |||
| Enterprise Value/Revenue (TTM) | -5.40 | |||
| Price | $1.79 | |||
| Enterprise Value/EBITDA (TTM) | 1.05 | |||
| Enterprise Value/EBIT | 1.05 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ZNTL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 71.11M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ZNTL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 212 433 3791 | |||
| Address | 1359 Broadway New York, NY 10018 | |||
| Website | zentalis.com | |||
| Country | United States | |||
| Year Founded | 2014 | |||
| Profitability | ZNTL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -515.94% | |||
| Profit Margin | -442.02% | |||
| Management Effectiveness | ZNTL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -25.24% | |||
| Return on Equity | -- | |||
| Income Statement | ZNTL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 40.56M | |||
| Total Revenue (TTM) | 40.56M | |||
| Revenue Per Share | $0.57 | |||
| Gross Profit (TTM) | 40.56M | |||
| EBITDA (TTM) | -207.96M | |||
| EBIT (TTM) | -209.27M | |||
| Net Income (TTM) | -179.28M | |||
| Net Income Avl. to Common (TTM) | -179.28M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 27.70% | |||
| EPS Diluted (TTM) | -2.53 | |||
| EPS Diluted Growth (Q YOY) | 28.19% | |||
| Balance Sheet | ZNTL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 391.25M | |||
| Cash Per Share (Q) | $5.50 | |||
| Total Current Assets (Q) | 400.27M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 354.33M | |||
| Current Ratio (Q) | 7.294 | |||
| Book Value Per Share (Q) | $4.98 | |||
| Total Assets (Q) | 450.66M | |||
| Total Current Liabilities (Q) | 54.88M | |||
| Total Debt (Q) | 43.27M | |||
| Total Liabilities (Q) | 96.33M | |||
| Total Common Equity (Q) | 354.33M | |||
| Cash Flow | ZNTL - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 102.22M | |||
| Cash from Financing (TTM) | 108.00K | |||
| Net Change in Cash (TTM) | -69.43M | |||
| Levered Free Cash Flow (TTM) | -85.85M | |||
| Cash from Operations (TTM) | -171.76M | |||
